<DOC>
	<DOCNO>NCT00743288</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop growth cancer cell , either kill cell stop dividing . Panobinostat may stop growth cancer cell block enzymes need cell growth . Giving melphalan together panobinostat may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose melphalan give together panobinostat treat patient recurrent multiple myeloma .</brief_summary>
	<brief_title>Melphalan Panobinostat ( LBH589 ) Treatment Patients With Recurrent Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum tolerate dose ( MTD ) determine dose-limiting toxicity ( DLT ) panobinostat combination melphalan patient relapse refractory multiple myeloma . ( Phase I ) - To determine dose regimen use Phase II portion study . ( Phase I ) - To determine efficacy evidence response rate ( combined complete response , good partial response , partial response , minimal response ) patient treat regimen . ( Phase II ) Secondary - To obtain preliminary evidence efficacy combination LBH589 melphalan patient relapse refractory multiple myeloma . ( Phase I ) - To determine safety tolerability regimen patient . ( Phase II ) - To determine time disease progression , time response , duration response patient treat regimen . ( Phase II ) - To determine progression-free survival overall survival patient treat regimen . ( Phase II ) OUTLINE : This multicenter , phase I , dose-escalation study follow phase II study . Patients receive oral panobinostat daily day 1 , 3 , 5 , 8 , 10 , 12 oral melphalan daily day 1 , 3 5 . Treatment repeat every 28 day 8 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Inclusion criterion : Diagnosis multiple myeloma , base follow criterion : Major criterion Plasmacytomas tissue biopsy ( 1 ) Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) ( 2 ) Monoclonal immunoglobulin ( Ig ) spike serum electrophoresis , IgG &gt; 3.5 g/dL IgA &gt; 2.0 g/dL , kappa lambda light chain excretion &gt; 1 g/day 24hour urine protein electrophoresis ( 3 ) Minor Criteria Bone marrow plasmacytosis ( 1030 % plasma cell ) ( ) Monoclonal immunoglobulin present less magnitude give major criterion ( b ) Lytic bone lesion © ) Normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL , IgG &lt; 600 mg/dL ( ) Meets follow set multiple myeloma diagnostic criterion : Any two major criterion Major criterion 1 plus minor criterion b , c , Major criterion 3 plus minor criterion c Minor criterion , b , c , OR , b , Measurable disease , define monoclonal immunoglobulin spike serum electrophoresis ≥ 1 g/dL and/or urine monoclonal immunoglobulin spike ≥ 200 mg/24 hour , evidence lytic bone disease Must receive ≥ 1 prior treatment regimen OR refractory recent chemotherapy Relapsed follow stabilization response standard firstline chemotherapy ( e.g. , vincristine , doxorubicin hydrochloride , prednisone melphalan prednisone ) firstline highdose chemotherapy Refractory ( i.e. , failure achieve least complete partial response stable disease ) recent chemotherapy , whether contain systemic corticosteroid Prior treatment ≤ 4 day total 400 mg prednisone ( equivalent potency another steroid ) myeloma consider regimen Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Life expectancy &gt; 3 month Platelet count ≥ 75 x 10^9/L ( ≥ 50 x 10^9/L bone marrow extensively infiltrate ) Absolute neutrophil count ≥ 1.5 x 10^9/L ( ≥ 1.0 x 10^9/L bone marrow extensively infiltrate ) Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) ≤ 2.5 time upper limit normal ( ULN ) Serum bilirubin ≤ 1.5 time ULN Creatinine clearance ≥ 30 mL/min ; creatinine &gt; 10 mL/min &lt; 30 mL/min due significant myelomatous involvement kidney allow medical director approval Serum potassium ≥ low limit normal ( LLN ) Serum magnesium ≥ LLN Serum phosphorus ≥ LLN Prior localize radiotherapy Exclusion criterion : Plasma cell dyscrasia polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ( POEMS syndrome ) Plasma cell leukemia Pregnant nursing female ; fertile patient must use effective contraception Peripheral neuropathy &gt; grade 2 Impaired cardiac function clinically significant cardiac disease ( include congenital long QT syndrome , history presence sustain ventricular tachyarrhythmia ; history ventricular fibrillation Torsade de Pointes ; bradycardia , define heart rate ( HR ) &lt; 50 beat per minute ( bpm ) [ pacemaker allow provide HR ≥ 50 bpm ] ; correct QT interval &gt; 450 msec screen ECG ; leave ventricular ejection fraction normal screen ECHO multigated acquisition ( MUGA ) scan ; right bundle branch block leave anterior hemiblock ( bifascicular block ) ; myocardial infarction unstable angina within past 6 month ; New York Heart Association class IIIIV congestive heart failure ; uncontrolled hypertension ; history labile hypertension ; history poor compliance antihypertensive regimen ) Impaired gastrointestinal ( GI ) function GI disease may significantly alter absorption panobinostat Prior malignancy within past 5 year except basal cell squamous cell carcinoma carcinoma situ cervix Other concurrent severe and/or uncontrolled medical psychiatric condition ( e.g. , uncontrolled diabetes active uncontrolled infection ) , include abnormal laboratory value could cause unacceptable safety risk compromise protocol compliance Known positivity HIV hepatitis B C Severe hypercalcemia ( i.e. , serum calcium ≥ 14 mg/dL ) Significant history noncompliance medical regimen unwillingness inability comply instruction give study staff Concurrent medication risk prolong QT interval induce Torsades de Pointes Prior panobinostat Received chemotherapy , bortezomib , thalidomide , lenalidomide arsenic trioxide within 3 wks enrollment ( exception nitrosoureas within 6 wks enrollment ) Received corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within three week enrollment . Received immunotherapy within &lt; 8 week ; antibody within &lt; 4 week ; radiation therapy &gt; 30 % marrowbearing bone within &lt; 2 week prior start study treatment ; yet recover side effect therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>